All In Biotech

Drug Trial Radar · NCT03048825

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients with Myocardial Infarction / SYNERGY Stent Registry - Organization to Assess Strategies for Ischemic Syndromes 9

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 7,264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,264

Actual

Start

Feb 1, 2018

Primary completion

Aug 9, 2024

Study completion Aug 9, 2024

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Scientific Corporation; Canadian Institutes of Health Research (CIHR)
First posted
Feb 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CLEAR SYNERGY trial will study the long term effects of treatments following PCI to treat myocardial infarction. These treatments address both the culprit artery (PCI with SYNERGY stent) as well as the non-culprit arteries (randomization to routine colchicine and spironolactone).

Conditions

  • ST Elevation Myocardial Infarction
  • Non ST Elevation Myocardial Infarction

Interventions

  • ColchicineDrug

    Colchicine 0.5 mg once daily

  • SpironolactoneDrug

    Spironolactone 25 mg once daily

  • SYNERGY Bioabsorbable Polymer Drug-Eluting StentDevice

    Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.

  • Colchicine-PlaceboDrug

    Matching Colchicine-placebo once daily

  • Spironolactone-PlaceboDrug

    Matching Spironolactone-Placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Adverse Cardiac Events (MACE)Time frame: up to 1 year
  2. Composite of cardiovascular death, recurrent myocardial infarction, stroke, or unplanned ischemia driven revascularizationTime frame: through study completion, an estimated average of 3 years
  3. Total composite events of cardiovascular death or new or worsening heart failure (co-primary 1)Time frame: through study completion, an estimated average of 3 years
  4. Composite of cardiovascular death, new or worsening heart failure, recurrent myocardial infarction, or stroke (co-primary 2)Time frame: through study completion, an estimated average of 3 years

Locations

109 sites in 14 countries. Site status is shown where the registry gives one.

  • Central Cardiology

    Bakersfield, California

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • University of Illinois

    Chicago, Illinois

  • Prairie Education & Research Cooperative

    Springfield, Illinois

  • Community Hospital

    Munster, Indiana

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • New Mexico Heart Institute

    Albuquerque, New Mexico

  • NYU Langone Medical Center

    New York, New York

  • The Christ Hospital Lindner Research Center

    Cincinnati, Ohio

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Rhode Island Hospital

    Providence, Rhode Island

  • Bankstown-Lidcombe hospital

    Bankstown, New South Wales, Australia

  • SWSLHD - Campbelltown

    Campbelltown, New South Wales, Australia

  • SWSLHD - Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Peninsula Health

    Frankston, Victoria, Australia

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Kelowna General Hospital

    Kelowna, British Columbia, Canada

  • Fraser Clinical Trials

    New Westminster, British Columbia, Canada

  • Victoria Heart Institute Foundation

    Victoria, British Columbia, Canada

  • William Osler Health

    Brampton, Ontario, Canada

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

  • Kingston Health Science Centre

    Kingston, Ontario, Canada

  • St. Mary's General Hospital

    Kitchener, Ontario, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • York PCI Group Inc

    Newmarket, Ontario, Canada

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

  • Niagara Health System

    Saint Catharines, Ontario, Canada

  • Scarborough Cardiology Research Associates Inc.

    Scarborough Village, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Toronto General Hospital, University Health Network

    Toronto, Ontario, Canada

  • Windsor Regional Hospital

    Windsor, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Institut Universitaire de Cardiologie et de Pneumologie - ULAVAL

    Québec, Quebec, Canada

  • CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont

    Sherbrooke, Quebec, Canada

  • PVRI - Regina General Hospital

    Regina, Saskatchewan, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Czech Center University Hospital Brno

    Brno, Czechia

Showing 40 of 109 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.